InnoCan Pharma (XCNQ:INNO) Risk Assessment

View and export this data going back to 2019. Start your Free Trial

What is InnoCan Pharma Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of InnoCan Pharma is: No Data: Cannot be evaluated.

Competitive Comparison of InnoCan Pharma's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, InnoCan Pharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCan Pharma's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InnoCan Pharma's Risk Assessment distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's Risk Assessment falls into.

InnoCan Pharma (XCNQ:INNO) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

InnoCan Pharma Risk Assessment Related Terms

Thank you for viewing the detailed overview of InnoCan Pharma's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCan Pharma (XCNQ:INNO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (XCNQ:INNO) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

INNPF:USA IP4:Germany

Address

1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7

Website

https://www.innocanpharma.com

InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

InnoCan Pharma (XCNQ:INNO) Headlines

From GuruFocus

Innocap, Inc.'s Current Activities

By Marketwired Marketwired • 05-24-2018

President of Innocap, Inc. is in Singapore

By Marketwired Marketwired • 05-03-2018

Innocap, Inc. Year End Message To Shareholders

By PRNewswire PRNewswire • 12-14-2020

Unique Logistics Holdings, Inc. and Innocap, Inc. Complete Reverse Merger and Financing

By PRNewswire PRNewswire • 10-27-2020

Innocap, Inc. Current Activities - Salvage Ship Has Departed Singapore For Recovery Operations

By Marketwired Marketwired • 06-28-2018

President of Innocap, Inc. is in Singapore

By GlobeNewswire GlobeNewswire • 05-03-2018